CA3171958A1 - Inhalational therapy for covid-19 - Google Patents

Inhalational therapy for covid-19 Download PDF

Info

Publication number
CA3171958A1
CA3171958A1 CA3171958A CA3171958A CA3171958A1 CA 3171958 A1 CA3171958 A1 CA 3171958A1 CA 3171958 A CA3171958 A CA 3171958A CA 3171958 A CA3171958 A CA 3171958A CA 3171958 A1 CA3171958 A1 CA 3171958A1
Authority
CA
Canada
Prior art keywords
mesylate
subject
pharmaceutical composition
composition
camostat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3171958A
Other languages
English (en)
French (fr)
Inventor
Takeshi Irie
Ouathek Ouerfelli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of CA3171958A1 publication Critical patent/CA3171958A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3171958A 2020-03-18 2021-03-18 Inhalational therapy for covid-19 Pending CA3171958A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062991561P 2020-03-18 2020-03-18
US62/991,561 2020-03-18
PCT/US2021/022997 WO2021188815A1 (en) 2020-03-18 2021-03-18 Inhalational therapy for covid-19

Publications (1)

Publication Number Publication Date
CA3171958A1 true CA3171958A1 (en) 2021-09-23

Family

ID=77771385

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3171958A Pending CA3171958A1 (en) 2020-03-18 2021-03-18 Inhalational therapy for covid-19

Country Status (5)

Country Link
US (1) US20230165826A1 (enExample)
EP (1) EP4121037A4 (enExample)
JP (1) JP2023518269A (enExample)
CA (1) CA3171958A1 (enExample)
WO (1) WO2021188815A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021202708A1 (en) * 2020-03-31 2021-10-07 Ensysce Biosciences, Inc. Methods for treating viral infections with nafamostat
EP4267125A4 (en) * 2020-12-22 2024-06-26 Ege Universitesi Development of an innovative inhalation formulation of nafamostat mesylate for the management of covid-19
CN118121605B (zh) * 2024-02-28 2025-09-09 中国科学院武汉病毒研究所 去甲乌药碱在防治新型冠状病毒中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0859503A (ja) * 1994-08-26 1996-03-05 Teijin Ltd ペプチド・蛋白質性薬物の経口、経粘膜投与用リポソーム製剤
US7034013B2 (en) * 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
JP2003089632A (ja) * 2001-09-17 2003-03-28 Otsuka Pharmaceut Factory Inc 注射用水性製剤
JP2005139085A (ja) * 2003-11-04 2005-06-02 Ono Pharmaceut Co Ltd 顆粒
AU2004311478A1 (en) * 2003-12-31 2005-07-21 Cydex Pharmaceuticals, Inc. Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US20070020196A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension
GB0507577D0 (en) * 2005-04-14 2005-05-18 Novartis Ag Organic compounds
DE102011108346A1 (de) * 2011-07-25 2013-01-31 Philipps-Universität Marburg Verwendung von Hemmstoffen der TMPRSS2 als Arzneimittel
BR112015003851A2 (pt) * 2012-08-21 2017-08-08 Glaxo Group Ltd composições compreendendo um domínio variável único e mesilato de camostato (cm)
RU2622747C2 (ru) * 2015-10-22 2017-06-19 федеральное государственное бюджетное учреждение "Федеральный научно-исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации (ФГБУ "ФНИЦЭМ им. Н.Ф. Гамалеи" Минздрава России) Способ и средство для лечения реактивного артрита хламидийной этиологии
JP2023512628A (ja) * 2020-01-21 2023-03-28 アカデミー オブ ミリタリー メディカル サイエンシズ ＳＡＲＳ－ＣｏＶ－２感染症の治療における安息香酸塩化合物の利用

Also Published As

Publication number Publication date
EP4121037A1 (en) 2023-01-25
WO2021188815A1 (en) 2021-09-23
US20230165826A1 (en) 2023-06-01
EP4121037A4 (en) 2024-03-20
JP2023518269A (ja) 2023-04-28

Similar Documents

Publication Publication Date Title
US11744895B2 (en) Intranasal epinephrine formulations and methods for the treatment of disease
US8986738B2 (en) Inhalative and instillative use of semifluorinated alkanes as an active substance carrier in the intrapulmonary area
ES2792682T3 (es) Métodos para el tratamiento de enfermedades pulmonares con estabilizadores de mastocitos
ES2285743T3 (es) Uso de un farmaco anticancerigeno no encapsulado para la preparacion de una formulacion para tratar neoplasias mediante inhlacion.
CA3171958A1 (en) Inhalational therapy for covid-19
JPH09512523A (ja) 肺血管収縮及び喘息を治療する方法
PL180318B1 (pl) oraz sposób wytwarzania preparatu farmaceutycznego odpowiedniegodo nebulizacji zawierajacego propionian flutikazonu PL PL PL PL PL PL
JP2009510077A (ja) 抗生物質製剤、単位用量、キットおよび方法
ES2928050T3 (es) Peptidomimético de horquilla beta con actividad inhibidora de elastasa y formas de dosificación en aerosol del mismo
ES2935684T3 (es) Formulaciones de epinefrina intranasales y métodos para el tratamiento de enfermedades
US20230355517A1 (en) Use of active substances with antiviral, anti malarial, and/or mucolytic properties in the treatment of viral lung diseases including covid-19 by soft mist inhaler or vibration mesh technology nebulizer through inhalation route
AU2021326382B2 (en) Use of a heparin composition in the treatment of viral lung diseases, acute and/or chronic lung diseases by soft mist inhaler or vibration mesh technology nebulizer through inhalation route
BR112021009572A2 (pt) métodos e composições para prevenção ou tratamento de exacerbações agudas com imunoglobulina policlonal
AU2022261974A1 (en) Compositions of interleukin-1 receptor antagonist
WO2021211923A1 (en) Compositions and methods for treating disease
WO2025186422A1 (en) Treatment and prevention of respiratory diseases
WO2025186423A1 (en) Immunoglobulin composition and method of generating an aerosol
CA3204080A1 (en) Compositions, devices, and methods for treating respiratory disorders
TR2023001692T2 (tr) Anti̇vi̇ral, anti̇malaryal ve/veya mukoli̇ti̇k özelli̇kli̇ etki̇n maddeleri̇n yumuşak buğu i̇nhaler veya ti̇treşi̇mli̇ elek teknoloji̇si̇ nebuli̇zer vasitasiyla i̇nhale yolla covid-19 dahi̇l vi̇ral akci̇ğer hastaliklarinin tedavi̇si̇nde kullanimi
Myrdal et al. Pulmonary Delivery of Drugs by Inhalation

Legal Events

Date Code Title Description
W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250902

R00 Party data change recorded

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R00-R113 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF ADDRESS OR METHOD OF CORRESPONDENCE REQUEST RECEIVED

Effective date: 20250903

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251103

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260102

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260202